TNFAIP8 promotes cisplatin resistance in cervical carcinoma cells by inhibiting cellular apoptosis

  • Authors:
    • Suxia Wu
    • Weihua Li
    • Zhenghui Wu
    • Tianran Cheng
    • Ping Wang
    • Na Li
    • Xiaonan Liang
    • Mengmeng Chi
    • Shuman Zhang
    • Yuanfang Ma
    • Yanyun Li
    • Lihui Chai
  • View Affiliations

  • Published online on: February 26, 2019     https://doi.org/10.3892/ol.2019.10076
  • Pages: 4667-4674
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cervical cancer is the second most prevalent malignant tumor in women worldwide. Failure of successful treatment is most prevalent in patients with the metastatic disease and the chemotherapy refractory disease. Tumor necrosis factor α‑induced protein 8 (TNFAIP8) serves as an anti‑apoptotic and pro‑oncogenic protein, and is associated with cancer progression and poor prognosis in a number of different cancer types. However, the physiological and pathophysiological roles of TNFAIP8 in cervical carcinogenesis and development remain poorly understood. In the present study, it was demonstrated that TNFAIP8 protein expression levels were significantly increased in cervical cancer tissues compared with the non‑tumor adjacent tissues using immunohistochemistry. Additionally, it was demonstrated that TNFAIP8 overexpression is associated with cisplatin resistance. Furthermore, depletion of TNFAIP8 impaired HeLa cell proliferation and viability in vitro, improved cisplatin sensitivity, and promoted cisplatin‑induced cellular apoptosis and death. Subsequent mechanistic analysis demonstrated that TNFAIP8 silencing promoted caspase‑8/-3 activation and p38 phosphorylation in HeLa cells treated with cisplatin, whereas apoptosis regulator B‑cell lymphoma‑2 expression was inhibited with TNFAIP8‑silenced HeLa cells following treatment with cisplatin. These data suggested that TNFAIP8 serves as an anti‑apoptotic protein against cisplatin‑induced cell death, which eventually leads to chemotherapeutic drug‑treatment failure. Therefore, the present data suggested that TNFAIP8 may be a promising therapeutic target for the treatment of cervical cancer.
View Figures
View References

Related Articles

Journal Cover

May-2019
Volume 17 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wu S, Li W, Wu Z, Cheng T, Wang P, Li N, Liang X, Chi M, Zhang S, Ma Y, Ma Y, et al: TNFAIP8 promotes cisplatin resistance in cervical carcinoma cells by inhibiting cellular apoptosis. Oncol Lett 17: 4667-4674, 2019
APA
Wu, S., Li, W., Wu, Z., Cheng, T., Wang, P., Li, N. ... Chai, L. (2019). TNFAIP8 promotes cisplatin resistance in cervical carcinoma cells by inhibiting cellular apoptosis. Oncology Letters, 17, 4667-4674. https://doi.org/10.3892/ol.2019.10076
MLA
Wu, S., Li, W., Wu, Z., Cheng, T., Wang, P., Li, N., Liang, X., Chi, M., Zhang, S., Ma, Y., Li, Y., Chai, L."TNFAIP8 promotes cisplatin resistance in cervical carcinoma cells by inhibiting cellular apoptosis". Oncology Letters 17.5 (2019): 4667-4674.
Chicago
Wu, S., Li, W., Wu, Z., Cheng, T., Wang, P., Li, N., Liang, X., Chi, M., Zhang, S., Ma, Y., Li, Y., Chai, L."TNFAIP8 promotes cisplatin resistance in cervical carcinoma cells by inhibiting cellular apoptosis". Oncology Letters 17, no. 5 (2019): 4667-4674. https://doi.org/10.3892/ol.2019.10076